系统性硬化症相关肺动脉高压的治疗进展  

Progress in the treatment of systemic sclerosis-associated pulmonary arterial hypertension

作　　者：朱轩池(综述) 刘秀梅(审校)[2] ZHU Xuanchi;LIU Xiumei(First Clinical College,Shanxi Medical University,Taiyuan 030001;Department of Rheumatology and Immunology,First Hospital of Shanxi Medical University,Taiyuan 030001,China)

机构地区：[1]山西医科大学第一临床医学院,太原030001 [2]山西医科大学第一医院风湿免疫科,太原030001

出　　处：《临床与病理杂志》2021年第7期1696-1702,共7页Journal of Clinical and Pathological Research

摘　　要：肺动脉高压(pulmonary arterial hypertension,PAH)是系统性硬化症(systemic sclerosis,SSc)肺部受累最常见的并发症之一,也是SSc患者最主要的死亡原因。近年来,随着各种新型靶向药物的应用以及治疗策略的改进,系统性硬化症相关肺动脉高压(systemic sclerosis-associated pulmonary arterial hypertension,SSc-PAH)患者的生存率有了明显的提升。Pulmonary arterial hypertension(PAH)is one of the most common complications of pulmonary involvement in systemic sclerosis(SSc),and it is also the leading cause of death in patients with SSc.In recent years,with the application of new targeted drugs and the improvement of treatment strategies,the survival rate of patients with systemic sclerosis-associated pulmonary arterial hypertension(SSc-PAH)has been greatly increased.

关 键 词：系统性硬化症相关肺动脉高压 肺血管扩张剂 新型靶向药物 初始联合治疗 

分 类 号：R54[医药卫生—心血管疾病]